Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Depreciation and Depletion (2023 - 2025)

Lisata Therapeutics (LSTA) has disclosed Depreciation and Depletion for 3 consecutive years, with $26000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation and Depletion rose 13.04% year-over-year to $26000.0, compared with a TTM value of $99000.0 through Sep 2025, up 10.0%, and an annual FY2024 reading of $100000.0, changed 0.0% over the prior year.
  • Depreciation and Depletion was $26000.0 for Q3 2025 at Lisata Therapeutics, roughly flat from $26000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $60000.0 in Q2 2023 and bottomed at $11000.0 in Q4 2023.
  • Average Depreciation and Depletion over 3 years is $28000.0, with a median of $26000.0 recorded in 2025.
  • Peak annual rise in Depreciation and Depletion hit 90.91% in 2024, while the deepest fall reached 55.0% in 2024.
  • Year by year, Depreciation and Depletion stood at $11000.0 in 2023, then soared by 90.91% to $21000.0 in 2024, then rose by 23.81% to $26000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for LSTA at $26000.0 in Q3 2025, $26000.0 in Q2 2025, and $26000.0 in Q1 2025.